Sexual Dysfunction Induced by Serotonin Reuptake Antidepressants

Labbate, Lawrence A.; Grimes, Jamie; Hines, A; Oleshansky, Marvin A.; Arana, George W.

doi:10.1080/00926239808414663

Cited by 113 publications

(31 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Orgasm delay, anorgasmia, delayed ejaculation and impotence are commonly observed in men and women under SSRI treatment. 2 Furthermore, some degree of erectile dysfunction secondary to SSRI administration appears in more than 40% of men. 3 Sexual alterations usually disappear when the treatment is interrupted.…”

Section: Introductionmentioning

confidence: 99%

“…4 Paroxetine is a representative compound of the SSRI class that has been extensively used in the clinical practice 5 and, like other compounds of its class, has been reported to induce sexual dysfunction. [1][2][3]6 It is able to inhibit in vitro and in vivo the synthesis of nitric oxide (NO) 7 which is a key mediator of penile smooth muscle relaxation and penile erection. 8,9 We have previously reported that paroxetine impairs erectile responses to cavernosal nerve stimulation in rats when administered either chronically or acutely.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vardenafil reverses erectile dysfunction induced by paroxetine in rats

Angulo¹,

Bischoff

Gabancho³

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

Selective serotonin reuptake inhibitors (SSRIs) are associated with a high incidence of impotence. Paroxetine is an extensively used SSRI that has been shown to impair erectile function in patients, to induce erectile dysfunction and to inhibit nitric oxide synthase (NOS) activity and NO production in animal models. NO is a key mediator of penile erection. Vardenafil is a type 5 phosphodiesterase inhibitor that potentiates NO-mediated responses in isolated trabecular smooth muscle and penile erection in men in clinical trials. The aim of this study was to evaluate the effects of vardenafil on the impairment of erectile responses produced by paroxetine in the rat model. Application of cavernosal nerve electrical stimulation (CNES) produced frequency-related intracavernosal pressure (ICP) increases, which were inhibited by the NOS inhibitor N G -nitro-l-arginine (0.3 mg/kg) and potentiated by vardenafil (0.3 mg/kg). Acute paroxetine treatment (10 mg/kg) significantly reduced ICP-responses to CNES. This inhibition was completely reversed by vardenafil (0.3 mg/kg) administration. The results show that the erectile dysfunction induced by paroxetine in rats can be effectively treated with vardenafil, suggesting that the use of this compound could be a reasonable therapeutic approach to treating erectile dysfunction associated with SSRI administration.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vardenafil reverses erectile dysfunction induced by paroxetine in rats

Angulo¹,

Bischoff

Gabancho³

et al. 2003

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…Initially, it appeared that sexual side effects were more common in men than women. However, more recent studies have found similar rates of SSRI-induced sexual dysfunction in both sexes (47,48). Clinical series and studies in men only suggest that the SSRIs as a class cause orgasmic delay (49).…”

Section: Antidepressantsmentioning

confidence: 98%

Female Sexual Disorders: Psychiatric Aspects

Segraves

2002

Can J Psychiatry

View full text Add to dashboard Cite

Objective: This manuscript reviews the current information concerning female sexual dysfunction that is relevant to general psychiatric practice. Method: Research identified by the key words sexual dysfunction and prevalence, comorbidity, psychiatric drugs, or pharmacotherapy is reviewed. Results: Epidemiologic studies indicate that approximately 30% of female subjects between ages 18 and 59 years have sexual complaints of at least 3 months' duration in the past year. A high comorbidity with other psychiatric syndromes exists. Many psychiatric drugs are associated with sexual dysfunction. Drug treatments for female sexual dysfunction are being investigated. Conclusion: Knowledge concerning the treatment of female sexual dysfunction is important to the general psychiatric clinician.

show abstract

“…In healthy volunteers, the only adverse effect attributable to indalpine was EjD which was spontaneously reported by 67% of the subjects [Seppälä et al 1988]. In men treated for depression, delay in ejaculation and orgasmic dysfunction are the most significant sexual complications [Labbate et al 1998]. Initiation of treatment results in worsening of orgasm delay, orgasm satisfaction and overall sexual functioning [Piazza et al 1997].…”

Section: In Patients On Drug Treatment For Other Conditionsmentioning

confidence: 99%

A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men

Seyam

2013

Therapeutic Advances in Urology

View full text Add to dashboard Cite

BackgroundThere is an increasing interest in nonpremature ejaculatory dysfunction (non-PE EjD). The frontier of sexual medicine has shifted slowly from erectile dysfunction (ED) to premature ejaculation (PE) and now to non-PE EjD. Two factors have contributed to this shift. First is the search for new areas of research and of novel treatments and second is the better characterization of ejaculatory disorders. The development of questionnaires that better characterize the type of ejaculatory dysfunction (EjD) has helped to identify the problem with more precision in different populations.Interest in the global sexual practice patterns gave insight into the prevalence of non-PE EjD in different areas of the world. Within the non-PE EjD itself, a shift in focus occurred over the years. Early and related to prostatic surgery and retroperitoneal lymph node dissection (RPLND) retrograde ejaculation was reported. With the development of α-blockers and finasteride, retrograde ejaculation, EjD and/or orgasmic dysfunction were reported as A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men Raouf SeyamAbstract Introduction: A better understanding of ejaculatory disorders has led to an increasing interest in nonpremature ejaculatory dysfunction (non-PE EjD). Current reviews on the subject use a symptom-based classification to describe ejaculatory dysfunction even when it is a single case report. While these reviews provide important information on the disorder, a clearer picture of the prevalence of non-PE EjD in relation to the community and various pathophysiologic states is needed. Objectives: The objective of this study was to provide a systematic review of studies of non-PE EjD excluding single case reports. Methods: A systematic review of Medline for terms including ejaculation, orgasm or hematospermia. Association with terms delay, pain or headache was made. The search was restricted to male gender and articles written in English. Abstracts were reviewed and those mainly concerned with premature ejaculation were excluded. Results: A total of 333 articles on non-PE EjD were identified. The condition was reported in community-based studies. In certain patient populations, non-PE EjD was commonly reported in association with antidepressant and antipsychotic treatments, in patients with chronic prostatitis/chronic pelvic pain syndrome, patients with lower urinary tract symptoms particularly in association with medical or surgical treatment, patients with retroperitoneal surgery and in patients with neurological diseases. Few articles were concerned with treatment options. Conclusion: There is a significant prevalence of non-PE EjD in the community and in association with particular disease states or as a side effect of medical or surgical interventions. There is a need to direct efforts to prevent and treat these conditions. Keywords: anhedonia, aspermia, ejaculation, epidemiology, headache, hemospermia, orgasm, pain, prevalence adverse events. It became clear ...

show abstract

Sexual Dysfunction Induced by Serotonin Reuptake Antidepressants

Cited by 113 publications

References 3 publications

Vardenafil reverses erectile dysfunction induced by paroxetine in rats

Vardenafil reverses erectile dysfunction induced by paroxetine in rats

Female Sexual Disorders: Psychiatric Aspects

A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men

Contact Info

Product

Resources

About